Welcome to our dedicated page for Xbiotech news (Ticker: XBIT), a resource for investors and traders seeking the latest updates and insights on Xbiotech stock.
XBiotech Inc (NASDAQ: XBIT) is a biosciences and clinical-stage biopharmaceutical company that regularly issues detailed updates on its therapeutic antibody programs, corporate actions and governance matters. Its news flow centers on the development of True Human™ antibody therapies targeting oncology, inflammatory diseases, infectious diseases, cardiovascular disease, rheumatology and stroke.
Readers of the XBiotech news page can find company announcements on key clinical trials, including randomized, double‑blind, placebo‑controlled studies for its Natrunix antibody in advanced pancreatic cancer and rheumatoid arthritis, as well as Phase I dose‑escalation work for its stroke candidate Hutrukin. The company’s releases describe study designs, endpoints, patient populations and top‑line findings, along with the company’s interpretation of safety, tolerability and outcome trends.
Beyond clinical data, XBiotech’s news also covers operational developments such as plans to expand its Austin, Texas campus with a new research and development facility to support commercialization and infectious disease programs. Corporate and capital markets updates, including a modified Dutch auction tender offer to repurchase common shares, appear alongside these scientific and operational disclosures.
Governance and leadership items, such as the appointment of lead investigators for clinical programs and the selection of medical and financial experts to the board of directors and its committees, are also reported through company news. Investors and observers who follow XBIT news can use this page to review historical announcements on pipeline progress, campus expansion, share repurchase activity and board composition, and to monitor how the company communicates developments in its True Human™ antibody platform over time.
XBiotech Inc. (NASDAQ: XBIT) announced it has identified True Human antibodies that could serve as a potential therapy against SARS-CoV2, the virus causing COVID-19. This discovery arose from collaboration with BioBridge Global, utilizing proprietary screening technology to analyze blood samples from individuals who recovered quickly from the virus. XBiotech's antibodies effectively block the virus and promote natural clearance. The company continues to expand its pipeline, including developing multiple therapeutic candidates and enhancing its manufacturing capabilities.
XBiotech Inc. (NASDAQ: XBIT) announces progress in developing a novel anti-IL-1⍺ antibody to combat inflammation. This new product aims to replace a prior antibody sold for $750 million. The company has successfully engineered a cell-based production system for the new antibody, which targets diseases like cancer and arthritis. Significant findings suggest potential for a blockbuster therapy, as recent research indicates the antibody can reduce stroke-related brain injury. XBiotech also plans to expand its manufacturing facilities to support ongoing projects.
XBiotech Inc. (NASDAQ: XBIT) announced significant findings in the journal Circulation regarding its anti-IL-1⍺ antibody. The study, led by Dr. Giovanni Camici, indicates this antibody can reduce brain damage and neurological deficits in experimental stroke cases. Results showed a 36% reduction in brain damage in treated animals. XBiotech is set to begin human clinical studies for its stroke candidate in 2021, addressing a critical need for therapies targeting reperfusion injury, which currently has no approved treatment.
Summary not available.